Changes in Beneficial Ownership · 4
ACADIA Pharmaceuticals Inc.
ACADNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-06012026_060610.xml
Filing details
- Report period
- 2026-05-29
- Issuer
- ACADIA PHARMACEUTICALS INC
- Issuer CIK
- 0001070494
- Trading symbol
- ACAD
Reporting owner 1
- Name
- Ndu Adora
- Reporting owner CIK
- 0001865210
- Relationship
- Director
- Address
- C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO, CA, 92130
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-05-29 | M · Form 4 | 8,107 | A | [F1] | 32,908 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | [F1] | 2026-05-29 | M · Form 4 | 8,107 | D | 0 | [F2] | [F2] | Common Stock | 8,107 | 0 | D |
| Director Stock Options (Right to Buy) | 21.66 | 2026-05-29 | A · Form 4 | 16,004 | A | 0 | [F3] | 2036-05-28 | Common Stock | 16,004 | 16,004 | D |
| Restricted Stock Units | [F1] | 2026-05-29 | A · Form 4 | 9,311 | A | 0 | [F4] | [F4] | Common Stock | 9,311 | 9,311 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
Footnotes
- F1
- Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.↩ 1↩ 2↩ 3
- F2
- The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.↩ 1↩ 2
- F3
- The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.↩ 1
Signature 1
- Signed
- /s/ Jennifer J. Rhodes, Attorney-in-Fact
- Date
- 2026-06-01
Company context
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.